Sabre Insurance Group PLC

Declaration of Voting Results & Voting Rights Announcements • Oct 3, 2025

National Storage Mechanism | Additional information

RNS Number : 9075B

Sabre Insurance Group PLC

03 October 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

3 October 2025

Sabre Insurance Group plc

("Sabre" or the "Company")

Transaction in Own Shares

and

Total Voting Rights

The Company announces that in accordance with the authority given by its shareholders at its Annual General Meeting on 22 May 2025 and pursuant to the Company's share buy-back announced on 01 July 2025, it has purchased for cancellation through Panmure Liberum Limited, the following ordinary shares in the capital of the Company ("Ordinary Shares"):

Date of purchase:	2 October 2025
Aggregate number of ordinary shares purchased:	35,000
Trading venue:	London Stock Exchange
Lowest price paid per share (p):	138.60
Highest price paid per share (p):	140.20
Average price paid per share (p):	139.42

Following cancellation of the above Ordinary Shares, the Company will have 246,600,000 Ordinary Shares in issue. No Ordinary Shares are held in treasury.

This number represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Investor enquiries	01306 747 272
Sabre Insurance Group plc	[email protected]
Geoff Carter / Adam Westwood
Media enquiries	020 7260 2700
Teneo	[email protected]
James Macey White / Ffion Dash

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSFLFITIILFIIE